logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

What the Aimmune and Nestlé Health Science agreement tells us

Aimmune Therapeutics (AIMT) has news. A lot of it is from a successful phase 3 trial for its peanut allergy drug as well as other news that boosts our conviction that this product is, indeed, important and has a good...

Read More

November 14, 2018

0

Compugen: A New Important Patent from Europe and Much More

Compugen: In the NEWS Compugen ( CGEN ) was granted a new patent for the composition of COM701 or backup antibodies for the treatment of cancer by the European Patent Office ( EPO ). The EPO Patent No. 3295951 titled,...

Read More

April 22, 2020

0

Loxo Oncology product Vitrakvi® has been granted FDA approval. The real meaning of the approval

As we expected in our posting yesterday under Today’s Highlights, the U.S. Food and Drug Administration (FDA) approved Loxo Oncology's (LOX O )   Vitrakvi ®  (larotrectinib) , the first oral TRK inhibitor for adult and pediatric patients with solid tumors...

Read More

November 27, 2018

0

Vertex: Offering proof of leadership in treating Cystic Fibrosis

Vertex Pharmaceuticals’ triple combination, which added the corrector VX-659 to the tezacaftor and ivacaftor combination, resulted in statistically significant improvements in lung function (percent predicted forced expiratory volume in one second, or ppFEV 1 ) in two Phase 3 studies...

Read More

November 29, 2018

0

Moderna: Speeding down the Road Towards Developing a Prophylactic Vaccine Against the Novel Coronavirus (SARS-CoV-2)

Moderna Submitted an IND for Its mRNA Vaccine Candidate for Novel Coronavirus  Moderna ( MRNA ) announced that it has submitted an Investigational New Drug ( IND ) application to the U.S. Food and Drug Administration (FDA) for its mRNA...

Read More

April 28, 2020

0

Gilead's CAR T Product Yescarta Demonstrates Positive Survival Results

Gilead's CAR-T Product Yescarta Results Kite , a  Gilead ( GILD ) subsidiary, announced new data from the ZUMA-1 trial of the CAR T Yescarta (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma. The data from the pivotal...

Read More

December 8, 2019

0

Celgene has important CAR T presentations at ASH

At the 60th American Society of Hematology (ASH)  Annual Meeting    CAR T is Still a Star With all the pessimistic views critics have sprayed around in the past few years about the cell therapy for cancer, the CAR T...

Read More

December 4, 2018

0

Alexion Pharmaceuticals to Acquire Portola at $18 Per Share

Alexion to Acquire Portola Alexion ( ALXN ) and Portola ( PTLA ) entered into a definitive merger agreement and Alexion acquired Portola. The Terms of the Merger A subsidiary of Alexion will commence a tender offer to acquire all...

Read More

May 5, 2020

0

Exelixis initiates a phase 3 trial with cabozantinib combination for previously untreated liver cancer

Exelixis (EXEL) and  Ipsen (Euronext: IPN; ADR: IPSEY)   announced the initiation of COSMIC-312. A phase 3 pivotal trial of cabozantinib (CABOMETYX ® ) in combination with atezolizumab (T ECENTRIQ ® ) versus sorafenib, in previously untreated advanced hepatocellular carcinoma ( H...

Read More

December 6, 2018

0

Exelixis and Genentech (Roche) Combination Beats Untreated BRAF V600-Mutation Positive Advanced Melanoma

Exelixis Positive Results from IMspire 150 Exelixis ( EXEL ) announced positive results from IMspire 150;  the phase 3 trial of atezolizumab (TECENTRIQ®), cobimetinib (COTELLIC®) and vemurafenib (ZELBORAF®) in people with previously untreated BRAF V600 mutation-positive advanced melanoma.  The IMspire150...

Read More

December 13, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 76
  • 77
  • 78
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy